Arcadia Biosciences
RKDA
25 hedge funds and large institutions have $17.6M invested in Arcadia Biosciences in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
4% less funds holding
Funds holding: 26 → 25 (-1)
6% less capital invested
Capital invested by funds: $18.7M → $17.6M (-$1.06M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LRPA
L. Roy Papp & Associates
Phoenix,
Arizona
|
+$695K |
| 2 |
Citigroup
New York
|
+$10.6K |
| 3 |
Goldman Sachs
New York
|
+$8.5K |
| 4 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
+$6.37K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$80.7K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$27.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.89K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.25K |
RKDA Hedge Fund Activity: Q1 2016 in Review
25 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q1 2016, worth a combined $17.6M — down 5.7% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RKDA and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was L. Roy Papp & Associates, opening a new position worth an estimated $695K. The largest seller was UBS O'Connor, cutting an estimated $80.7K.
- 25 institutional investors held Arcadia Biosciences (RKDA) as of Q1 2016, down from 26 in Q4 2015.
- Funds reported $17.6M of Arcadia Biosciences stock for Q1 2016, down 5.7% quarter-over-quarter.
- 2 funds opened new Arcadia Biosciences positions in Q1 2016 and 3 closed out, a net change of -1 holder.
- The largest Arcadia Biosciences buyer in Q1 2016 was L. Roy Papp & Associates, an estimated $695K added.
- The largest Arcadia Biosciences seller in Q1 2016 was UBS O'Connor, an estimated $80.7K sold.
Based on aggregated 13F filings for Q1 2016.